Sanofi and GlaxoSmithKline To Surge Amid Receiving $2.1 Billion To Fight COVID-19, Here is Why

‘Operation Warp Speed’ initiative from Federal authorities is aiding reliable biotech companies like Vaxart and Moderna. The turn came to Sanofi (NASDAQ: SNY) and Glax (NYSE: GSK) that already received rewards from the UK government to speed up the development of the COVID-19 vaccine and preserve for its population only.

SNY and GSK are not penny stock since they have no negative EPS. However, there has been no significant volatility in the stocks. They may rise at least 10% soon because short term traders can’t afford huge volumes of them.

Investors are to stay alert by adding the stocks to watchlist while reading news that can impact on stock movement.